NYC-based Precision Neuroscience, which develops brain-computer interfaces, raised a $250M Series D at a $1B+ valuation, taking its total funding to $430M

Brain-computer interface devices can now be safely removed and are receiving FDA clearance for future clinical use.

Precision Neuroscience, a startup developing brain-computer interfaces (BCI), has secured $250 million in Series D funding, bringing its total raised to $430 million and achieving a valuation exceeding $1 billion. The oversubscribed round was co-led by Pershing Square Inc. and the Ackman Oxman Institute, with participation from numerous other investment firms. Founded in 2021, Precision's core technology, the Layer 7 Cortical Interface, aims to record high-resolution neural signals with minimal invasiveness. The company has completed over 100 patient procedures across 18 medical institutions and received FDA clearance for its device. The new funding will support clinical development, regulatory processes, and commercialization efforts. Precision also has a commercial partnership with Medtronic and operates its own manufacturing facility for electrode arrays.

The substantial funding and high valuation for Precision Neuroscience underscore a significant investor appetite for advanced neurotechnology. This capital infusion enables Precision to move aggressively towards commercialization, potentially accelerating the timeline for widespread clinical adoption of BCIs for neurological conditions. The company's focus on minimally invasive and removable technology, coupled with regulatory milestones like FDA clearance, suggests a strategy geared towards overcoming key barriers to market entry.

This development signals a maturation in the BCI field, moving beyond research and into scalable manufacturing and clinical deployment. Precision's integrated approach, encompassing technology development, clinical trials, regulatory engagement, and manufacturing control, offers a potential model for other companies in the deep tech space. The involvement of major investment firms indicates a growing belief in the commercial viability and transformative potential of brain-computer interfaces.